Evidence map›Paper›PMID 31796124›Full record

ArticleActa neuropathologica communications2019

A post-translational modification signature defines changes in soluble tau correlating with oligomerization in early stage Alzheimer's disease brain.

Ebru Ercan-Herbst, Jens Ehrig, David C Schöndorf, Annika Behrendt, Bernd Klaus, Borja Gomez Ramos, Nuria Prat Oriol, Christian Weber, Dagmar E Ehrnhoefer

Open access · goldAbstract read
In one paragraph

Article in Acta neuropathologica communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 119 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Monoterpene-rich essential oil fromToxicology research · 2025
    Article
  6. Locus coeruleus-entorhinal cortex tract integrity is linked to plasma tau and glial fibrillary acidic protein.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  7. Review
  8. Review
  9. Current Understanding of Protein Aggregation in Neurodegenerative Diseases.International journal of molecular sciences · 2025
    Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Plasma p-tau immunoassays in clinical research for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Ebru Ercan-HerbstBioMed X Innovation Center, Im Neuenheimer Feld 515, 69120, Heidelberg, Germany.
Jens EhrigB CUBE - Center for Molecular Bioengineering, Technische Universitaet Dresden, 01307, Dresden, Germany.
David C SchöndorfBioMed X Innovation Center, Im Neuenheimer Feld 515, 69120, Heidelberg, Germany.
Annika BehrendtBioMed X Innovation Center, Im Neuenheimer Feld 515, 69120, Heidelberg, Germany.
Bernd KlausCentre for Statistical Data Analysis, European Molecular Biology Laboratory (EMBL), 69117, Heidelberg, Germany.
Borja Gomez RamosBioMed X Innovation Center, Im Neuenheimer Feld 515, 69120, Heidelberg, Germany.
Nuria Prat OriolBioMed X Innovation Center, Im Neuenheimer Feld 515, 69120, Heidelberg, Germany.
Christian WeberBioMed X Innovation Center, Im Neuenheimer Feld 515, 69120, Heidelberg, Germany.
Dagmar E EhrnhoeferBioMed X Innovation Center, Im Neuenheimer Feld 515, 69120, Heidelberg, Germany. ehrnhoefer@bio.mx.ORCID 0000-0003-3411-5415
BioMed X Institute · DECenter for Systems Biology Dresden · DEEuropean Molecular Biology Laboratory · DEUniversity of Luxembourg · LU

Funding

AbbVie Deutschland n.a.
6 · The paper itself

Abstract

Tau is a microtubule-binding protein that can receive various post-translational modifications (PTMs) including phosphorylation, methylation, acetylation, glycosylation, nitration, sumoylation and truncation. Hyperphosphorylation of tau is linked to its aggregation and the formation of neurofibrillary tangles (NFTs), which are a hallmark of Alzheimer's disease (AD). While more than 70 phosphorylation sites have been detected previously on NFT tau, studies of oligomeric and detergent-soluble tau in human brains during the early stages of AD are lacking. Here we apply a comprehensive electrochemiluminescence ELISA assay to analyze twenty-five different PTM sites as well as tau oligomerization in control and sporadic AD brain. The samples were classified as Braak stages 0-I, II or III-IV, corresponding to the progression of microscopically detectable tau pathology throughout different brain regions. We found that soluble tau multimers are strongly increased at Braak stages III-IV in all brain regions under investigation, including the temporal cortex, which does not contain NFTs or misfolded oligomers at this stage of pathology. We additionally identified five phosphorylation sites that are specifically and consistently increased across the entorhinal cortex, hippocampus and temporal cortex in the same donors. Three of these sites correlate with tau multimerization in all three brain regions, but do not overlap with the epitopes of phospho-sensitive antibodies commonly used for the immunohistochemical detection of NFTs. Our results thus suggest that soluble multimers are characterized by a small set of specific phosphorylation events that differ from those dominating in mature NFTs. These findings shed light on early PTM changes of tau during AD pathogenesis in human brains.

Indexed as

AgedAged, 80 and overAlzheimer DiseaseBrainFemaleHumansInduced Pluripotent Stem CellsMalePhosphorylationProtein Processing, Post-Translationaltau ProteinsMAPT protein, humantau ProteinsAlzheimer’s diseasePosttranslational modificationsTauTau oligomerization

Identifiers

PMID31796124
PMCPMC6892178
OpenAlexW2993562248

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.